CoChat
Sign Up
Cited by 27Cancer Research and TreatmentsGut microbiota and healthOral microbiology and periodontitis research

Fusobacterium nucleatum carcinogenesis and drug delivery interventions

Open access
Chen, Zhenzhen, Huang, Leaf·2024·Advanced Drug Delivery Reviews
DOI 10.1016/j.addr.2024.115319PMC PMC11459907
Open this paper in CoChat — free account

Abstract

The microbiome has emerged as a significant biomarker and modulator in cancer development and treatment response. Recent research highlights the notable role of Fusobacterium nucleatum (F. nucleatum) in various tumor types, including breast, colorectal, esophageal, gastric, pancreatic, and lung cancers. Accumulating evidence suggests that the local microbial community forms an integral component of the tumor microenvironment, with bacterial communities within tumors displaying specificity to tumor types. Mechanistic investigations indicate that tumor-associated microbiota can directly influence tumor initiation, progression, and responses to chemotherapy or immunotherapy. This article presents a comprehensive review of microbial communities especially F. nucleatum in tumor tissue, exploring their roles and underlying mechanisms in tumor development, treatment, and prevention. When the tumor-associated F. nucleatum is killed, the host immune response is activated to recognize tumor cells. Bacteria epitopes restricted by the host antigens, can be identified for future anti-bacteria/tumor vaccine development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2024.115319

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Phage-mediated targeting of Fusobacterium nucleatum reduces protumorigenic inflammation in preclinical models.

    “phage-mediated targeting of F. nucleatum has been shown to reduce protumorigenic inflammation and enhance chemotherapy responsiveness in preclinical models [67]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [67]

    The Phage drug delivery system section (page unavailable) reports that phage targeting of F. nucleatum suppressed recruitment of immunosuppressive cells in animal colorectal-tumor experiments. It also reports improved outcomes when the phage-based treatment was combined with chemotherapy. It does not report a measured reduction in protumorigenic inflammation; that wording extends the reported immune-microenvironment finding. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • Phage-mediated targeting of Fusobacterium nucleatum enhances chemotherapy responsiveness in preclinical models.

    “phage-mediated targeting of F. nucleatum has been shown to reduce protumorigenic inflammation and enhance chemotherapy responsiveness in preclinical models [67]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [67]

    The Phage drug delivery system section reports that an F. nucleatum-targeting phage formulation improved the effects of first-line chemotherapy on colorectal tumors, and describes supporting animal experiments. It also reports reduced recruitment of immunosuppressive cells, but does not establish that the treatment reduced protumorigenic inflammation specifically. No page number is available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Phage-mediated targeting of F. nucleatum in colorectal cancer models reduces tumor burden, attenuates protumorigenic inflammation, and enhances responsiveness to chemotherapy.

    “phage-mediated targeting of F. nucleatum in colorectal cancer models has been shown to reduce tumor burden, attenuate protumorigenic inflammation, and enhance responsiveness to chemotherapy [51,67]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [67]

    The “Phage drug delivery system” section (page unavailable) reports that an F. nucleatum-targeting M13 phage–silver nanoparticle treatment inhibited tumor cells and improved colorectal tumor treatment when combined with chemotherapy. It also reports reduced recruitment of immunosuppressive cells, but does not show that the phage treatment attenuated protumorigenic inflammation specifically. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 77

  1. [2]Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, Ketelaars SLC, Cheng K, Vervier K, Shental N, Bussi Y, Rotkopf R, Levy R, Benedek G, Trabish S, Dadosh T, Levin-Zaidman S, Geller LT, Wang K, Greenberg P, Yagel G, Peri A, Fuks G, Bhardwaj N, Reuben A, Hermida L, Johnson SB, Galloway-Peña JR, Shropshire WC, Bernatchez C, Haymaker C, Arora R, Roitman L, Eilam R, Weinberger A, Lotan-Pompan M, Lotem M, Admon A, Levin Y, Lawley TD, Adams DJ, Levesque MP, Besser MJ, Schachter J, Golani O, Segal E, Geva-Zatorsky N, Ruppin E, Kvistborg P, Peterson SN, Wargo JA, Straussman R, Samuels Y, Identification of bacteria-derived HLA-bound peptides in melanoma, Nature. 592 (2021) 138– 143. 10.1038/s41586-021-03368-8. 33731925 PMC9717498 · DOI · Paper page
  2. [3]Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R, The microbiome and human cancer, Science (80-.). 371 (2021). 10.1126/science.abc4552. PMC8767999 33766858 · DOI · Paper page
  3. [4]Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, Yajuk O, Isaacson B, Abed J, Maalouf N, Nissan A, Sandbank J, Yehuda-Shnaidman E, Ponath F, Vogel J, Mandelboim O, Granot Z, Straussman R, Bachrach G, Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression, Nat. Commun 11 (2020) 1– 12. 10.1038/s41467-020-16967-2. 32591509 PMC7320135 · DOI · Paper page
  4. [6]Wang N, Fang JY, Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer, Trends Microbiol. 31 (2023) 159– 172. 10.1016/j.tim.2022.08.010. 36058786 · DOI
  5. [7]Gao Y, Zou T, Xu P, Wang Y, Jiang Y, Chen YX, Chen H, Hong J, Fang JY, Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer, Neoplasia (United States). 35 (2023) 100850. 10.1016/j.neo.2022.100850. PMC9664554 36371909 · DOI
  6. [8]Hieken TJ, Chen J, Hoskin TL, Walther-Antonio M, Johnson S, Ramaker S, Xiao J, Radisky DC, Knutson KL, Kalari KR, Yao JZ, Baddour LM, Chia N, Degnim AC, The microbiome of aseptically collected human breast tissue in benign and malignant disease, Sci. Rep 6 (2016) 1– 10. 10.1038/srep30751. 27485780 PMC4971513 · DOI
  7. [9]Hsieh Y, Kuo W, Hsu W, Tung S, Li C, Fusobacterium Nucleatum-Induced Tumor Mutation Burden, Cancers (Basel). 15 (2022) 269. 36612265 PMC9818776
  8. [10]Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J, Consensus molecular subtypes and, (n.d.). 10.1038/nrc.2016.126. · DOI
  9. [11]Siegel RL, Miller KD, Jemal A, Cancer Statistics, 2018, 68 (2018) 7– 30. 10.3322/caac.21442. 29313949 · DOI
  10. [13]Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, Serna G, Mulet N, Landolfi S, Ramon S, Fasani R, Aguirre AJ, Ng K, Élez E, Ogino S, Tabernero J, Fuchs CS, Hahn WC, Nuciforo P, Meyerson M, Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer, Science (80-.). 358 (2017) 1443– 1448. 10.1126/science.aal5240. PMC5823247 29170280 · DOI · Paper page
  11. [16]Zhao H, Chu M, Huang Z, Yang X, Ran S, Hu B, Zhang C, Liang J, Variations in oral microbiota associated with oral cancer, Sci. Rep 7 (2017) 1– 10. 10.1038/s41598-017-11779-9. 28924229 PMC5603520 · DOI
  12. [17]Boehm ET, Thon C, Kupcinskas J, Steponaitiene R, Skieceviciene J, Canbay A, Malfertheiner P, Link A, Fusobacterium nucleatum is associated with worse prognosis in Lauren’s diffuse type gastric cancer patients, Sci. Rep 10 (2020) 1– 12. 10.1038/s41598-020-73448-8. 33004953 PMC7530997 · DOI
  13. [18]Udayasuryan B, Ahmad RN, Nguyen TTD, Umaña A, Roberts LDM, Sobol P, Jones SD, Munson JM, Slade DJ, Verbridge SS, Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling, Sci. Signal 15 (2022). 10.1126/scisignal.abn4948. PMC9732933 36256708 · DOI
  14. [19]Guo S, Chen J, Chen F, Zeng Q, Liu WL, Zhang G, Exosomes derived from Fusobacterium nucleatum -infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16, Gut. 70 (2021) 1507– 1519. 10.1136/gutjnl-2020-321187. 33172926 · DOI
  15. [20]Qu X, Yin F, Pei M, Chen Q, Zhang Y, Lu S, Zhang X, Liu Z, Li X, Chen H, Zhang Y, Qin H, Modulation of Intratumoral Fusobacterium nucleatum to Enhance Sonodynamic Therapy for Colorectal Cancer with Reduced Phototoxic Skin Injury, ACS Nano. 17 (2023) 11466– 11480. 10.1021/acsnano.3c01308. 37201179 PMC10311605 · DOI
  16. [21]Chen S, Su T, Zhang Y, Lee A, He J, Ge Q, Wang L, Si J, Zhuo W, Wang L, Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7, Gut Microbes. 11 (2020) 511– 525. 10.1080/19490976.2019.1695494. 31910722 PMC7524269 · DOI
  17. [22]Li X, Ma Y, Xin Y, Ma F, Gao H, Tumor-Targeting Nanoassembly for Enhanced Colorectal Cancer Therapy by Eliminating Intratumoral Fusobacterium nucleatum, ACS Appl. Mater. Interfaces (2023). 10.1021/acsami.3c01210. 36916659 · DOI
  18. [23]Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW, Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA Adhesin, Cell Host Microbe. 14 (2013) 195– 206. 10.1016/j.chom.2013.07.012. 23954158 PMC3770529 · DOI · Paper page
  19. [24]Tong Y, Lu G, Wang Z, Hao S, Zhang G, Sun H, Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer, Front. Immunol 14 (2023) 1– 13. 10.3389/fimmu.2023.1154818. PMC10189021 37207216 · DOI
  20. [25]Li Y, Hively WP, Varmus HE, Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer, Oncogene. 19 (2000) 1002– 1009. 10.1038/sj.onc.1203273. 10713683 · DOI
  21. [26]Fu A, Yao B, Dong T, Chen Y, Yao J, Liu Y, Li H, Bai H, Liu X, Zhang Y, Wang C, Guo Y, Li N, Cai S, Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer, Cell. 185 (2022) 1356– 1372.e26. 10.1016/j.cell.2022.02.027. 35395179 · DOI · Paper page
  22. [27]Abed J, Maalouf N, Manson AL, Earl AM, Parhi L, Emgård JEM, Klutstein M, Tayeb S, Almogy G, Atlan KA, Chaushu S, Israeli E, Mandelboim O, Garrett WS, Bachrach G, Colon Cancer-Associated Fusobacterium nucleatum May Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System, Front. Cell. Infect. Microbiol 10 (2020) 1– 12. 10.3389/fcimb.2020.00400. 32850497 PMC7426652 · DOI
  23. [28]Jiang SS, Le Xie Y, Xiao XY, Kang ZR, Lin XL, Zhang L, Li CS, Qian Y, Xu PP, Leng XX, Wang LW, Tu SP, Zhong M, Zhao G, Chen JX, Wang Z, Liu Q, Hong J, Chen HY, Chen YX, Fang JY, Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer, Cell Host Microbe. 31 (2023) 781– 797.e9. 10.1016/j.chom.2023.04.010. 37130518 · DOI
  24. [29]Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M, Genomic analysis identifies association of Fusobacterium with colorectal carcinoma, Genome Res. 22 (2012) 292– 298. 10.1101/gr.126573.111. 22009990 PMC3266036 · DOI · Paper page
  25. [30]Janati AI, Karp I, Laprise C, Sabri H, Emami E, Detection of Fusobaterium nucleatum in feces and colorectal mucosa as a risk factor for colorectal cancer: a systematic review and meta-analysis, Syst. Rev 9 (2020) 1– 15. 10.1186/s13643-020-01526-z. 33272322 PMC7716586 · DOI
  26. [31]Dong X, Pan P, Zheng D-W, Bao P, Zeng X, Zhang X-Z, Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer, Sci. Adv 6 (2020). 10.1126/sciadv.aba1590. PMC7228756 32440552 · DOI
  27. [32]Li Z, Shi C, Zheng J, Guo Y, Fan T, Zhao H, Jian D, Cheng X, Tang H, Ma J, Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma, BMC Microbiol. 21 (2021) 1– 14. 10.1186/s12866-021-02352-6. 34717543 PMC8556942 · DOI
  28. [33]Zhao LY, Mei JX, Yu G, Lei L, Zhang WH, Liu K, Chen XL, Kołat D, Yang K, Hu JK, Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications, Signal Transduct. Target. Ther 8 (2023). 10.1038/s41392-023-01406-7. PMC10183032 37179402 · DOI · Paper page
  29. [34]Galeano Niño JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, Futran N, Houlton J, Sather C, Sicinska E, Taylor A, Minot SS, Johnston CD, Bullman S, Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer, Nature. 611 (2022) 810– 817. 10.1038/s41586-022-05435-0. 36385528 PMC9684076 · DOI · Paper page
  30. [35]Wang M, Rousseau B, Qiu K, Huang G, Zhang Y, Su H, Le Bihan-Benjamin C, Khati I, Artz O, Foote MB, Cheng Y-Y, Lee K-H, Miao MZ, Sun Y, Bousquet P-J, Hilmi M, Dumas E, Hamy A-S, Reyal F, Lin L, Armistead PM, Song W, Vargason A, Arthur JC, Liu Y, Guo J, Zhou X, Nguyen J, He Y, Ting JP-Y, Anselmo AC, Huang L, Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses., Nat. Biotechnol (2023). 10.1038/s41587-023-01957-8. PMC12892252 37749267 · DOI
  31. [36]Zhang Y, Zhang L, Zheng S, Li M, Xu C, Jia D, Qi Y, Hou T, Wang L, Wang B, Li A, Chen S, Si J, Zhuo W, Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis, Gut Microbes. 14 (2022). 10.1080/19490976.2022.2038852. PMC8890384 35220887 · DOI
  32. [37]Guo P, Tian Z, Kong X, Yang L, Shan X, Dong B, Ding X, Jing X, Jiang C, Jiang N, Yu Y, FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2, J. Exp. Clin. Cancer Res 39 (2020) 1– 13. 10.1186/s13046-020-01677-w. 32993749 PMC7523382 · DOI
  33. [38]Chen Y, Chen Y, Zhang J, Cao P, Su W, Deng Y, Zhan N, Fu X, Huang Y, Dong W, Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression, Theranostics. 10 (2020) 323– 339. 10.7150/thno.38870. 31903123 PMC6929621 · DOI
  34. [39]Kong C, Yan X, Zhu Y, Zhu H, Luo Y, Liu P, Ferrandon S, Kalady MF, Gao R, He J, Yin F, Qu X, Zheng J, Gao Y, Wei Q, Ma Y, Liu JY, Qin H, Fusobacterium nucleatum promotes the development of colorectal cancer by activating a cytochrome p450/epoxyoctadecenoic acid axis via tlr4/keap1/nrf2 signaling, Cancer Res. 81 (2021) 485– 498. 10.1158/0008-5472.CAN-21-0453. 34162680 · DOI
  35. [40]Wu J, Li Q, Fu X, Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity, Transl. Oncol 12 (2019) 846– 851. 10.1016/j.tranon.2019.03.003. 30986689 PMC6462820 · DOI
  36. [41]Yin H, Miao Z, Wang L, Su B, Liu C, Jin Y, Wu B, Han H, Yuan X, Fusobacterium Nucleatum Promotes Liver Metastasis in Colorectal Cancer by Regulating the Hepatic Immune Niche and Altering Gut Microbiota, Aging (Albany. NY). 14 (2022) 1941– 1958. 10.18632/aging.203914. 35212644 PMC8908934 · DOI
  37. [42]Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F, Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin, Nature. 547 (2017) 99– 103. 10.1038/nature22393. 28459430 · DOI · Paper page
  38. [43]Hayashi M, Ikenaga N, Nakata K, Luo H, Zhong PS, Date S, Oyama K, Higashijima N, Kubo A, Iwamoto C, Torata N, Abe T, Yamada Y, Ohuchida K, Oda Y, Nakamura M, Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis, Cancer Sci. 114 (2023) 3666– 3678. 10.1111/cas.15901. 37438965 PMC10475786 · DOI
  39. [44]Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS, Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment, Cell Host Microbe. 14 (2013) 207– 215. 10.1016/j.chom.2013.07.007. 23954159 PMC3772512 · DOI · Paper page
  40. [45]Ganesan K, Guo S, Fayyaz S, Zhang G, Xu B, Targeting programmed fusobacterium nucleatum fap2 for colorectal cancer therapy, Cancers (Basel). 11 (2019) 13– 15. 10.3390/cancers11101592. PMC6827134 31635333 · DOI
  41. [46]Lu X, Xu Q, Tong Y, Zhang Z, Dun G, Feng Y, Tang J, Han D, Mao Y, Deng L, He X, Li Q, Xiang Y, Wang FC, Zeng D, Tang B, Mao X, Long non-coding RNA EVADR induced by Fusobacterium nucleatum infection promotes colorectal cancer metastasis, Cell Rep. 40 (2022) 111127. 10.1016/j.celrep.2022.111127. 35858553 · DOI
  42. [47]Kim HS, Kim CG, Kim WK, Kim KA, Yoo J, Min BS, Paik S, Shin SJ, Lee H, Lee K, Kim H, Shin EC, Kim TM, Ahn JB, Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers, Front. Cell. Infect. Microbiol 13 (2023) 1– 12. 10.3389/fcimb.2023.1101291. PMC10028079 36960042 · DOI
  43. [48]Zhang M, Wang Y, Yu L, Zhang Y, Wang Y, Shang Z, Xin Y, Li X, Ning N, Zhang Y, Zhang X, Fusobacterium nucleatum promotes colorectal cancer metastasis by excretion of miR-122–5p from cells via exosomes, IScience. 26 (2023) 107686. 10.1016/j.isci.2023.107686. PMC10485600 37694140 · DOI
  44. [49]Holt RA, Oncomicrobial vaccines: The potential for a Fusobacterium nucleatum vaccine to improve colorectal cancer outcomes, Cell Host Microbe. 31 (2023) 141– 145. 10.1016/j.chom.2022.11.014. 36634619 · DOI
  45. [50]Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf J, Song SJ, Kanbar J, Miller-Montgomery S, Heaton R, Mckay R, Patel SP, Swafford AD, Knight R, Microbiome analyses of blood and tissues suggest cancer diagnostic approach, Nature. 579 (2020) 567– 574. 10.1038/s41586-020-2095-1. 32214244 PMC7500457 · DOI · Paper page
  46. [51]Maisonneuve C, Tsang DKL, Foerster EG, Robert LM, Mukherjee T, Prescott D, Tattoli I, Lemire P, Winer DA, Winer S, Streutker CJ, Geddes K, Cadwell K, Ferrero RL, Martin A, Girardin SE, Philpott DJ, Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells, Cell Rep. 34 (2021) 108677. 10.1016/j.celrep.2020.108677. 33503439 · DOI
  47. [52]Sakamoto Y, Mima K, Ishimoto T, Ogata Y, Imai K, Miyamoto Y, Akiyama T, Daitoku N, Hiyoshi Y, Iwatsuki M, Baba Y, Iwagami S, ichi Yamashita Y, Yoshida N, Komohara Y, Ogino S, Baba H, Relationship between Fusobacterium nucleatum and antitumor immunity in colorectal cancer liver metastasis, Cancer Sci. 112 (2021) 4470– 4477. 10.1111/cas.15126. 34464993 PMC8586672 · DOI
  48. [53]Wu Z, Ma Q, Guo Y, You F, The Role of Fusobacterium nucleatum in Colorectal Cancer Cell Proliferation and Migration, Cancers (Basel). 14 (2022). 10.3390/cancers14215350. PMC9656216 36358769 · DOI
  49. [54]Goradel N. Hashemi, Heidarzadeh S, Jahangiri S, Farhood B, Mortezaee K, Khanlarkhani N, Negahdari B, Fusobacterium nucleatum and colorectal cancer: A mechanistic overview, J. Cell. Physiol 234 (2019) 2337– 2344. 10.1002/jcp.27250. 30191984 · DOI
  50. [55]Liang M, Liu Y, Zhang Z, Yang H, Dai N, Zhang N, Sun W, Guo Y, Kong J, Wang X, Wang M, Zhou F, Fusobacterium nucleatum induces MDSCs enrichment via activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance, Ann. Med 54 (2022) 989– 1003. 10.1080/07853890.2022.2061045. 35435776 PMC9891225 · DOI
  51. [56]Wu Y, Guo S, Chen F, Li Y, Huang Y, Liu W, Zhang G, Fn-Dps, a novel virulence factor of Fusobacterium nucleatum, disrupts erythrocytes and promotes metastasis in colorectal cancer, PLoS Pathog. 19 (2023). 10.1371/journal.ppat.1011096. PMC9873182 36693067 · DOI
  52. [57]Engevik MA, Danhof HA, Ruan W, Engevik AC, Chang-Graham AL, Engevik KA, Shi Z, Zhao Y, Brand CK, Krystofiak ES, Venable S, Liu X, Hirschi KD, Hyser JM, Spinler JK, Britton RA, Versalovic J, Fusobacterium nucleatum secretes outer membrane vesicles and promotes intestinal inflammation, MBio. 12 (2021) 1– 17. 10.1128/mBio.02706-20. PMC8092269 33653893 · DOI
  53. [58]Parhi L, Abed J, Shhadeh A, Alon-Maimon T, Udi S, Ben-Arye SL, Tam J, Parnas O, Padler-Karavani V, Goldman-Wohl D, Yagel S, Mandelboim O, Bachrach G, Placental colonization by Fusobacterium nucleatum is mediated by binding of the Fap2 lectin to placentally displayed Gal-GalNAc, Cell Rep. 38 (2022) 110537. 10.1016/j.celrep.2022.110537. 35320712 · DOI
  54. [59]Hsieh YY, Tung SY, Pan HY, Chang TS, Wei KL, Chen WM, Deng YF, Lu CK, Lai YH, Wu CS, Li C, Fusobacterium nucleatum colonization is associated with decreased survival of helicobacter pylori-positive gastric cancer patients, World J. Gastroenterol. 27 (2021) 7311– 7323. 10.3748/wjg.v27.i42.7311. 34876791 PMC8611209 · DOI
  55. [60]Chu S, Cheng Z, Yin Z, Xu J, Wu F, Jin Y, Yang G, Airway Fusobacterium is Associated with Poor Response to Immunotherapy in Lung Cancer, Onco. Targets. Ther 15 (2022) 201– 213. 10.2147/OTT.S348382. 35250279 PMC8896836 · DOI
  56. [61]Liu Y, Baba Y, Ishimoto T, Tsutsuki H, Zhang T, Nomoto D, Okadome K, Yamamura K, Harada K, Eto K, Hiyoshi Y, Iwatsuki M, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ohmuraya M, Wang X, Ajani JA, Sawa T, Baba H, Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma, Br. J. Cancer 124 (2021) 963– 974. 10.1038/s41416-020-01198-5. 33299132 PMC7921654 · DOI
  57. [62]Little A, Tangney M, Tunney MM, Buckley NE, Fusobacterium nucleatum: A novel immune modulator in breast cancer?, Expert Rev. Mol. Med 25 (2023). 10.1017/erm.2023.9. PMC10407221 37009688 · DOI
  58. [63]Pardoll DM, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer 12 (2012) 252– 264. 10.1038/nrc3239. 22437870 PMC4856023 · DOI · Paper page
  59. [65]June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC, CAR T cell immunotherapy for human cancer, Science (80-.). 359 (2018) 1361– 1365. 10.1126/science.aar6711. 29567707 · DOI · Paper page
  60. [66]Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin 68 (2018) 394– 424. 10.3322/caac.21492. 30207593 · DOI · Paper page
  61. [69]Hara H, Kawamura I, Nomura T, Tominaga T, Tsuchiya K, Mitsuyama M, Cytolysin-dependent escape of the bacterium from the phagosome is required but not sufficient for induction of the Th1 immune response against Listeria monocytogenes infection: Distinct role of listeriolysin o determined by cytolysin gene replacement, Infect. Immun 75 (2007) 3791– 3801. 10.1128/IAI.01779-06. 17517863 PMC1951982 · DOI
  62. [70]Andersson DI, Hughes D, Antibiotic resistance and its cost: Is it possible to reverse resistance?, Nat. Rev. Microbiol 8 (2010) 260– 271. 10.1038/nrmicro2319. 20208551 · DOI
  63. [71]Brown ED, Wright GD, Antibacterial drug discovery in the resistance era, Nature. 529 (2016) 336– 343. 10.1038/nature17042. 26791724 · DOI
  64. [72]Casadevall A, Pirofski LA, Host-pathogen interactions: Basic concepts of microbial commensalism, colonization, infection, and disease, Infect. Immun 68 (2000) 6511– 6518. 10.1128/IAI.68.12.6511-6518.2000. 11083759 PMC97744 · DOI
  65. [73]Celli J, Tsolis RM, Bacteria, the endoplasmic reticulum and the unfolded protein response: Friends or foes?, Nat. Rev. Microbiol 13 (2015) 71– 82. 10.1038/nrmicro3393. 25534809 PMC4447104 · DOI
  66. [74]Stewart MP, Sharei A, Ding X, Sahay G, Langer R, Jensen KF, In vitro and ex vivo strategies for intracellular delivery, Nature. 538 (2016) 183– 192. 10.1038/nature19764. 27734871 · DOI · Paper page
  67. [75]Park IS, Kim S, Yim Y, Park G, Choi J, Won C, Min DH, Multifunctional synthetic nano-chaperone for peptide folding and intracellular delivery, Nat. Commun 13 (2022) 1– 11. 10.1038/s41467-022-32268-2. 35931667 PMC9356039 · DOI
  68. [76]Li X, Niu J, Deng L, Yu Y, Zhang L, Chen Q, Zhao J, Wang B, Gao H, Amphiphilic polymeric nanodrug integrated with superparamagnetic iron oxide nanoparticles for synergistic antibacterial and antitumor therapy of colorectal cancer, Acta Biomater. 173 (2024) 432– 441. 10.1016/j.actbio.2023.11.019. 37984629 · DOI
  69. [77]Jia F, Yu Q, Wang R, Zhao L, Yuan F, Guo H, Shen Y, He F, Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression, Int. J. Mol. Sci 24 (2023). 10.3390/ijms24021469. PMC9865857 36674985 · DOI
  70. [78]Xie S, Wei L, Liu Y, Meng J, Cao W, Qiu B, Li X, Size-tunable nanogels for cascaded release of metronidazole and chemotherapeutic agents to combat Fusobacterium nucleatum-infected colorectal cancer, J. Control. Release 365 (2024) 16– 28. 10.1016/j.jconrel.2023.11.018. 37956925 · DOI
  71. [79]Zhao T, Wang X, Fu L, Yang K, Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response, Cancer Drug Resist. (2022) 424– 438. 10.20517/cdr.2021.144. 35800370 PMC9255244 · DOI
  72. [80]Ye J, Pei W, Zhu J, Li P, Liu H, Gao L, Ma C, Gu R, Ye S, Zhao D, Research progress on gel-based nanocomposites for diagnosis and treatment of respiratory diseases, Mater. Adv 4 (2023) 5431– 5452. 10.1039/d3ma00129f. · DOI
  73. [81]Song W, Tiruthani K, Wang Y, Shen L, Hu M, Dorosheva O, Qiu K, Kinghorn KA, Liu R, Huang L, Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis, Adv. Mater 30 (2018) 1– 7. 10.1002/adma.201805007. PMC6580426 30387230 · DOI
  74. [82]Ji G, Si X, Dong S, Xu Y, Li M, Yang B, Tang Z, Fang X, Huang L, Song W, Chen X, Manipulating Liver Bile Acid Signaling by Nanodelivery of Bile Acid Receptor Modulators for Liver Cancer Immunotherapy, Nano Lett. 21 (2021) 6781– 6791. 10.1021/acs.nanolett.1c01360. 34382807 · DOI
  75. [83]Thananimit S, Pahumunto N, Teanpaisan R, Characterization of Short Chain Fatty Acids Produced by Selected Potential Probiotic Lactobacillus Strains, Biomolecules. 12 (2022) 1– 17. 10.3390/biom12121829. PMC9775007 36551257 · DOI
  76. [84]Gasaly N, de Vos P, Hermoso MA, Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation, Front. Immunol 12 (2021) 1– 16. 10.3389/fimmu.2021.658354. PMC8187770 34122415 · DOI
  77. [85]Faass L, Hauke M, Stein SC, Josenhans C, Innate immune activation and modulatory factors of Helicobacter pylori towards phagocytic and nonphagocytic cells, Curr. Opin. Immunol 82 (2023) 102301. 10.1016/j.coi.2023.102301. 36933362 · DOI

Cited by

Sorted by citations

Authors
Chen, Z., & Huang, L.
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
Huang, Leaf
ORCID
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2024-06
Volume
209
Pages
115319
ISSN
0169-409X (ISSN-L)
DOI
10.1016/j.addr.2024.115319
PMC
PMC11459907
OpenAlex
W4394985075
Cited by
27
References
8
Citations by year
2026: 8 · 2025: 12 · 2024: 7
FWCI
1.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Advanced Drug Delivery Reviews (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute
  • National Institutes of Health (T32-CA196589-08)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords
Fusobacterium nucleatum, gut microbiota, tumor microbiome, carcinogenesis, tumor microenvironment, cancer immunotherapy, chemotherapy response, colorectal cancer, breast cancer, drug delivery
MeSH terms
Animals, Humans, Neoplasms, Drug Delivery Systems, Fusobacterium nucleatum, Tumor Microenvironment, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review